Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
23 September 2022Website:
http://www.biohaven.comNext earnings report:
28 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 23:52:49 GMTDividend
Analysts recommendations
Institutional Ownership
BHVN Latest News
NEW HAVEN, Conn. , Oct. 2, 2024 /PRNewswire/ -- Biohaven Ltd.
NEW HAVEN, Conn. , Oct. 1, 2024 /PRNewswire/ -- Biohaven Ltd.
NEW HAVEN, Conn. , Sept. 30, 2024 /PRNewswire/ -- Biohaven Ltd.
The pivotal BHV4157-206-RWE study evaluating Biohaven's pipeline candidate, troriluzole, for treating spinocerebellar ataxia meets its primary endpoint.
Biohaven Ltd. NYSE: BHVN has taken center stage in the biopharmaceutical sector after releasing positive results from its Phase 3 clinical trial for troriluzole, a drug being developed to treat spinocerebellar ataxia (SCA).
Biohaven (BHVN) shares surged after the company's troriluzole drug showed significant slowed progression of spinocerebellar ataxia, a rare neurological disease. George Tsilis shares how the promising results can mark the beginning of a long road to success for Biohaven.
Biohaven (BHVN) shares soared 15% Monday after the biotech firm announced positive results from a study of its experimental treatment for a rare neurological condition.
Shares of Biohaven climbed 13% premarket on Monday after the biotech company said its treatment for a rare neurological disorder slowed progress of the condition in a clinical trial.
Biohaven has met the main goal in a study evaluating its drug in patients with an inherited disease that mainly affects the brain, the company said on Monday.
Conference call and webcast to be held Monday, September 23, at 8:30am ET NEW HAVEN, Conn. , Sept. 20, 2024 /PRNewswire/ -- Biohaven Ltd.
- 1(current)
What type of business is Biohaven Pharmaceutical Holding?
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. was formerly a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.
What sector is Biohaven Pharmaceutical Holding in?
Biohaven Pharmaceutical Holding is in the Healthcare sector
What industry is Biohaven Pharmaceutical Holding in?
Biohaven Pharmaceutical Holding is in the Biotechnology industry
What country is Biohaven Pharmaceutical Holding from?
Biohaven Pharmaceutical Holding is headquartered in United States
When did Biohaven Pharmaceutical Holding go public?
Biohaven Pharmaceutical Holding initial public offering (IPO) was on 23 September 2022
What is Biohaven Pharmaceutical Holding website?
https://www.biohaven.com
Is Biohaven Pharmaceutical Holding in the S&P 500?
No, Biohaven Pharmaceutical Holding is not included in the S&P 500 index
Is Biohaven Pharmaceutical Holding in the NASDAQ 100?
No, Biohaven Pharmaceutical Holding is not included in the NASDAQ 100 index
Is Biohaven Pharmaceutical Holding in the Dow Jones?
No, Biohaven Pharmaceutical Holding is not included in the Dow Jones index
When was Biohaven Pharmaceutical Holding the previous earnings report?
No data
When does Biohaven Pharmaceutical Holding earnings report?
The next expected earnings date for Biohaven Pharmaceutical Holding is 28 February 2025